New injections for weight loss and diabetes: what they are and whether one is right for you

You've heard about these injections but aren't sure which one applies to your situation

It's genuinely confusing. Several brand names circulate (Mounjaro, Wegovy, Ozempic, Saxenda) and the overlap between weight loss and diabetes treatment makes it hard to know which, if any, applies to you. The two medicines most relevant to someone managing both weight and blood sugar are tirzepatide and semaglutide. Tirzepatide activates two receptors involved in appetite and glucose regulation simultaneously: GIP and GLP-1. Semaglutide targets GLP-1 alone. Both slow gastric emptying and reduce appetite; tirzepatide's dual action also affects fat storage differently at a cellular level, which may account for the larger average weight reductions seen in trials.

Ozempic is semaglutide, but at doses and in a formulation licensed by the MHRA specifically for type 2 diabetes, not for weight management. The NHS medicines page for tirzepatide sets this out clearly. If a prescriber has mentioned Ozempic for your diabetes, that is a separate clinical conversation to a weight-loss prescription. These distinctions matter because prescribing outside a licensed indication carries clinical and legal implications. Our prescribers at nume work only within UK-licensed indications.

The overlap between diabetes treatment and weight-loss injections is an area patients ask about often, and it deserves a straightforward answer rather than a vague one. If you have type 2 diabetes and a BMI that meets criteria, tirzepatide is licensed for both conditions simultaneously. That is not a loophole; it is its licensed use.

What the trial evidence actually shows, and where the uncertainty sits

SURMOUNT-1, published in the New England Journal of Medicine, followed 2,539 adults with obesity over 72 weeks. At the highest dose of 15mg, participants lost an average of around 20–21% of body weight. In SURMOUNT-5, a head-to-head comparison published in the NEJM in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. NICE's appraisal of tirzepatide (TA1026) drew on this evidence in recommending it for NHS use from December 2024.

Semaglutide's STEP 1 trial reported an average of around 15% body weight reduction over 68 weeks at the 2.4mg maintenance dose. These are averages across thousands of participants, some lost more, some less. The honest picture is that both medicines produce meaningful results in clinical settings, but neither is guaranteed to produce a specific outcome for any individual. Factors including which dose you reach, how well your body tolerates titration, your starting weight, and whether you make sustainable changes to eating patterns all influence the result.

For people who want to understand the safety evidence around diabetes injections used for weight loss, the short answer is that both tirzepatide and semaglutide have extensive trial data and post-market surveillance behind them, with Black Triangle (▼) status in the UK indicating active MHRA monitoring. They are not without side effects, which is covered below.

Side effects, safety signals and when to seek urgent help

The most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and burping. These are most noticeable after starting treatment or after a dose increase, and most people find they settle within a week or two. Fatigue, headache and injection-site reactions are also reported. The NHS patient information for these medicines and the manufacturer's Patient Information Leaflet cover the full list; always read the leaflet that comes with your pen.

One safety signal that requires specific mention: in January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known but infrequent side effect of GLP-1 medicines. Severe stomach pain (particularly pain that radiates through to the back, with or without vomiting) needs urgent medical attention, not a wait-and-see approach. Report any suspected side effects through the MHRA Yellow Card scheme.

Tirzepatide reduces absorption of oral contraceptive pills in the first four weeks of treatment and for four weeks after each dose increase; women using oral contraceptives should add a barrier method during those windows. Pregnancy, breastfeeding and trying to conceive are clear contraindications, these medicines are not recommended in any of those situations, and the prescriber discussion about stopping treatment and an appropriate washout period should happen well in advance of conception. If you're managing a complex medical history, our clinical team can work through your situation in detail. People curious about which injection is most appropriate for prediabetes will find a dedicated page covering that specific question.

Getting a prescription: NHS or private, and what to realistically expect

The NHS rollout of tirzepatide is phased. From June 2025, it became available to patients with a BMI of 40 or above alongside four or more of a defined list of qualifying conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes). Cohort 2 activated in June 2026, extending access to BMI 35–39.9 with four or more conditions. These criteria are strict. Even where a patient meets them, wrap-around lifestyle support is required and waiting times vary by area.

Private treatment through a GPhC-registered online pharmacy is the route people take when they don't meet NHS thresholds, don't want to wait, or want a same-day clinical review. At nume, a named GPhC-registered Independent Prescriber (not an automated system) reads your consultation the day you submit it. If you're clinically suitable and order before 12pm on a weekday, treatment is dispatched the same day and arrives via tracked DPD delivery the next working day. One transparent price covers the consultation, prescription, treatment and aftercare; there is no subscription and no hidden fee. For a full picture of how to access these medicines privately, the guide to getting weight-loss injections in the UK covers the steps clearly.

If you're still weighing up options, the overview of weight-loss injections available in the UK lays out what's licensed and how the different medicines compare, without pushing you toward any particular product. Patients based in Idaho can find locally relevant information on our weight loss injections Boise page, which covers access and eligibility in that area. The right choice is a clinical one, made with a prescriber who knows your full picture.